Praxis Precision Medicines Inc
NASDAQ:PRAX

Watchlist Manager
Praxis Precision Medicines Inc Logo
Praxis Precision Medicines Inc
NASDAQ:PRAX
Watchlist
Price: 269.28 USD 8.59%
Market Cap: 6.7B USD

Praxis Precision Medicines Inc
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Praxis Precision Medicines Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Praxis Precision Medicines Inc
NASDAQ:PRAX
Depreciation & Amortization
$358k
CAGR 3-Years
26%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$200.6m
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$525.1m
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
23%
No Stocks Found

Praxis Precision Medicines Inc
Glance View

Market Cap
6.7B USD
Industry
Biotechnology

In the realm of biotechnology, Praxis Precision Medicines Inc. has emerged as a distinctive player, navigating the intricate path of neuropsychiatric and neurological disorder treatment. Founded with a mission to develop therapies that directly address the underlying causes of brain disorders, Praxis capitalizes on the integration of genetic insights and brain circuitry. This approach fuels the company’s innovative pipeline, which aims to launch first-in-class or best-in-class treatments for conditions often considered unmanageable or neglected. By leveraging deep genetic knowledge and pioneering circuit-based methodologies, Praxis concentrates its research on specific neural pathways in the hope of crafting target-specific drugs, thereby enhancing both efficacy and safety for patients. Praxis Precision Medicines generates revenue primarily through the clinical development and eventual commercialization of its drug candidates. The company invests heavily in research and development, often funded by strategic partnerships, private investments, and public offerings. As Praxis advances its drug candidates through various phases of clinical trials, it also seeks to strike beneficial collaborations with larger pharmaceutical entities, thus securing upfront payments, milestone fees, and royalties. This business model allows Praxis to sustain its scientific endeavors while setting the stage for potential revenue streams, contingent upon the successful approval and market introduction of its innovative therapies. Through this cycle of rigorous R&D and strategic partnerships, Praxis aims to transform its cutting-edge research into tangible medical solutions, contributing to its growth and financial health.

PRAX Intrinsic Value
72.26 USD
Overvaluation 73%
Intrinsic Value
Price

See Also

What is Praxis Precision Medicines Inc's Depreciation & Amortization?
Depreciation & Amortization
358k USD

Based on the financial report for Dec 31, 2024, Praxis Precision Medicines Inc's Depreciation & Amortization amounts to 358k USD.

What is Praxis Precision Medicines Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
55%

Over the last year, the Depreciation & Amortization growth was -17%. The average annual Depreciation & Amortization growth rates for Praxis Precision Medicines Inc have been 26% over the past three years , 55% over the past five years .

Back to Top